Leniolisib for Primary Immunodeficiency
Trial Summary
What is the purpose of this trial?
This study is an exploratory, non-randomized, open-label, within-patient dose escalation study. The primary objective is to assess safety and tolerability of leniolisib. Secondary objectives include assessments of PK/PD, and to explore clinical efficacy measures with administration of three different dose levels of leniolisib.
Do I need to stop my current medications to join the trial?
You may need to stop certain medications before joining the trial. Specifically, you cannot use certain immunosuppressive medications, strong inhibitors or inducers of specific enzymes, or medications that act on certain transport proteins close to the time of starting the trial. If you are on abatacept, you can continue if your dose has been stable for over 3 months.
What data supports the effectiveness of the drug leniolisib for primary immunodeficiency?
Leniolisib has been shown to be effective in treating activated PI3Kδ syndrome (APDS), a type of primary immunodeficiency, by reducing lymph node size and increasing the percentage of certain immune cells, which indicates improved immune function. In clinical trials, patients taking leniolisib experienced significant improvements compared to those taking a placebo, with fewer side effects.12345
Is leniolisib safe for humans?
Leniolisib has been tested in a clinical trial for a condition called activated PI3Kδ syndrome (APDS), and it was generally well tolerated by participants. Fewer people taking leniolisib reported mild side effects compared to those taking a placebo, and it did not cause severe immune-related side effects seen with similar drugs.12367
How is the drug leniolisib unique for treating primary immunodeficiency?
Leniolisib is unique because it is an oral drug that specifically targets the PI3Kδ pathway, which is crucial for immune cell function, and it has shown both efficacy and tolerability in treating activated PI3Kδ syndrome (APDS), a type of primary immunodeficiency. Unlike other similar drugs, leniolisib selectively inhibits the δ isoform without causing severe immune-related side effects.12378
Research Team
Gulbu Uzel, M.D.
Principal Investigator
National Institutes of Health (NIH)
Eligibility Criteria
This trial is for people aged 12-75 with Primary Immunodeficiency (PID) who have certain blood issues, enlarged spleen or lymph nodes, specific blood pressure and heart rate ranges, lung disease related to PID, and genetic mutations linked to PID. It's not suitable for those with conditions that could explain their symptoms like iron-deficiency.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive leniolisib with a dose escalation regimen: 10 mg BID for 4 weeks, 30 mg BID for 4 weeks, and 70 mg BID for 12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment, with the EOS visit planned approximately 28 days after the last dose
Treatment Details
Interventions
- Leniolisib (PI3K Inhibitor)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pharming Technologies B.V.
Lead Sponsor
Aixial Group
Collaborator
Aixial Group
Industry Sponsor